Society Testimony

Testimony to FDA on Semaglutide

October 17, 2017

Endocrine Society Submitted Testimony to the Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee 

"The Society urges the FDA to give fair consideration of new options in combating this disease and to expedite the approval process for emerging therapies that, based on safety and efficacy data, have the potential to reduce complications and impact the progression of diabetes. "

arrow Read the Full Testimony

Last Updated:

Policy Communications

Take Action

Make Your Voice Heard

Take Action
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

ENDO 2020

Maximize Your Savings

Register Today
Bringing together leading experts, researchers, and the most respected clinicians in the field, ENDO represents a convergence of science and practice that highlights and facilitates breakthrough discoveries in the field of endocrinology.

Advance Registration Deadline: February 13, 2020

Bringing together leading experts, researchers, and the most respected clinicians in the field, ENDO represents a convergence of science and practice that highlights and facilitates breakthrough discoveries in the field of endocrinology.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!